HealthDay on MSN13d
FDA Approves More Broadly Protective Meningococcal Vaccine
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
Medscape16d
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration
Noninferiority criteria were not met for some pneumococcal conjugate serotypes ... and epidemiologic characteristics of meningococcal disease, vaccination has a major role in its prevention ...
Benzinga.com13d
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week
The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...
WebMD14d
FDA Approves 5-in-1 Vaccine Against Meningococcal Disease
These studies showed that the vaccine is effective, safe, and well-tolerated, with a safety profile similar to GSK’s licensed meningococcal vaccines, according to the news release by GSK.
Neurology Advisor5d
Meningococcal Vaccination Recommended Before Switch to Ravulizumab in NMOSD
For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.
Healio16d
FDA approves GSK’s pentavalent meningococcal vaccine
Penmenvy protects against meningococcal serotypes A, B, C, W and Y. CDC vaccine advisors are set to discuss recommendations for the vaccine on Feb. 26. The FDA approved GSK’s pentavalent ...
Medical Xpress15d
FDA approves more broadly protective meningococcal vaccine
The FDA has approved Penmenvy, a vaccine for individuals aged 10 to 25, targeting five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), which cause invasive meningococcal disease ...